Patent and Trademark Office NoticesPatent and Trademark Office Notices

INO Therapeutics, LLC d/b/a Ikaria, Inc.. 8, 431,163. IPR2015-00525. 1/5/2015. Praxair Distribution, Inc. &. Praxair, Inc.. INO ... INO Therapeutics, LLC d/b/a Ikaria, Inc.. 6, 321,229. IPR2015-00523. 1/5/2015. ServiceNow, Inc.. Hewlett-Packard Development ... INO Therapeutics, LLC d/b/a Ikaria, Inc.. 6, 322,901. IPR2015-00528. 1/5/2015. Nanoco Technologies, Ltd.. Massachusetts ... INO Therapeutics, LLC d/b/a Ikaria, Inc.. 8,119,358. IPR2015-00557. 1/13/2015. Boston Heart Diagnostics Corporation. Health ...
more infohttps://www.uspto.gov/web/offices/com/sol/og/2015/week09/TOC.htm

Patent and Trademark Office NoticesPatent and Trademark Office Notices

al., Owner of Record: Grifols Therapeutics Inc, Attorney or Agent: Carl B. Massey, Jr., Ex. Gp.: 1646 6,536,123, Re. S.N. 13/ ...
more infohttps://www.uspto.gov/web/offices/com/sol/og/2013/week08/TOC.htm

Home | Institute for Translational Medicine and Therapeutics | Perelman School of Medicine at the University of PennsylvaniaHome | Institute for Translational Medicine and Therapeutics | Perelman School of Medicine at the University of Pennsylvania

... supports research at the interface of basic and clinical research focusing on developing new and safer therapeutics. ITMAT ... The Institute for Translational Medicine and Therapeutics (ITMAT) ... Welcome to the Institute for Translational Medicine and Therapeutics. The Institute for Translational Medicine and Therapeutics ... Institute for Translational Medicine and Therapeutics. 3400 Civic Center Boulevard, Building 421. 10th Floor, Room 122. ...
more infohttp://www.itmat.upenn.edu

Gingivitis Diagnostics and Therapeutics Market - Scope, Size, Share, Analysis by 2025Gingivitis Diagnostics and Therapeutics Market - Scope, Size, Share, Analysis by 2025

... rising number of smoking people in the globe stimulate the growth of gingivitis diagnostics and therapeutics market ... Gingivitis Diagnostics and Therapeutics Market is anticipated to foresee tremendous growth rate in near future; ... Global Gingivitis Diagnostics and Therapeutics Market: Snapshot. The global market for gingivitis diagnostics and therapeutics ... Gingivitis Diagnostics And Therapeutics Market Size, Share, Growth, Sales, Trade, Shipment, Export Value And Volume With Sales ...
more infohttps://www.tmrresearch.com/gingivitis-diagnostics-therapeutics-market-

Indi Molecular Inks PCC Development Deal with Sigma, But Main Focus Now on Therapeutics | GenomeWebIndi Molecular Inks PCC Development Deal with Sigma, But Main Focus Now on Therapeutics | GenomeWeb

The shift back toward therapeutics marks a return to the companys initial focus, which it put on hold last year due to a ... Indi Molecular Inks PCC Development Deal with Sigma, But Main Focus Now on Therapeutics. Dec 19, 2014 ... Home » Indi Molecular Inks PCC Development Deal with Sigma, But Main Focus Now on Therapeutics ... Indi Molecular has shifted its focus from developing PCCs as research and diagnostic tools to therapeutics, CEO Albert Luderer ...
more infohttps://www.genomeweb.com/proteomics-protein-research/indi-molecular-inks-pcc-development-deal-sigma-main-focus-now

Hereditary Angioedema (HAE) Therapeutics - Pipeline Analysis 2017Hereditary Angioedema (HAE) Therapeutics - Pipeline Analysis 2017

Therapeutics - Pipeline Analysis 2017, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments ... Hereditary Angioedema (HAE) Therapeutics. Hereditary Angioedema (HAE) Therapeutics - Pipeline Analysis 2017, Clinical Trials & ... Some of the key players developing drugs for the treatment of HAE therapeutics include Shire plc, BioCryst Pharmaceuticals, Inc ... As of November 2017, the HAE therapeutics pipeline comprises of 20 drug candidates in different stages of development. ...
more infohttps://www.psmarketresearch.com/market-analysis/hereditary-angioedema-therapeutics-pipeline-analysis

Nektar TherapeuticsNektar Therapeutics

5)* Nektar Therapeutics (Name of Issuer) Common Stock (Title of Class of Securities) 640268108 (CUSIP Number) 06/30/2004 (Date ... on or about the date hereof, relating to the common stock of Nektar Therapeutics is filed on behalf of the undersigned. Dated: ... NEKTAR THERAPEUTICS CENTRAL INDEX KEY: 0000906709 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS ...
more infohttps://www.sec.gov/Archives/edgar/data/906709/000072888904000466/0000728889-04-000466.txt

Moderna Therapeutics | Science | AAASModerna Therapeutics | Science | AAAS

... therapeutics and vaccines, an entirely new drug technology that directs the bodys cells to produce intracellular or secreted ...
more infohttp://www.sciencemag.org/employer-profile/moderna-therapeutics

Therapeutics | ALZFORUMTherapeutics | ALZFORUM

202 Therapeutics View Results. Reset. AD Target / Therapy Types. The two tables below organize the therapeutics within this ... Therapeutics. This database provides a catalog of the therapeutics currently or previously tested as treatment for Alzheimers ... The number of therapeutics within each category is indicated according to the highest phase each therapeutic has achieved in U. ... Resolving Controversies on the Path to AD Therapeutics. 06 Oct 2011. *Treating Before Symptoms-ADCS Invites Ideas for Clinical ...
more infohttps://www.alzforum.org/therapeutics

Therapeutics | ALZFORUMTherapeutics | ALZFORUM

202 Therapeutics View Results. Reset. AD Target / Therapy Types. The two tables below organize the therapeutics within this ... Therapeutics. This database provides a catalog of the therapeutics currently or previously tested as treatment for Alzheimers ... The number of therapeutics within each category is indicated according to the highest phase each therapeutic has achieved in U. ... Resolving Controversies on the Path to AD Therapeutics. 06 Oct 2011. *Treating Before Symptoms-ADCS Invites Ideas for Clinical ...
more infohttps://www.alzforum.org/therapeutics?id=74

Nucleic Acid TherapeuticsNucleic Acid Therapeutics

Focuses on cutting-edge research and applications to find and examine new approaches using nucleic acids in therapeutics ... Nucleic Acid Therapeutics. • formerly Oligonucleotides. Co-Editors-in-Chief: Bruce A. Sullenger, PhD and Annemieke Aartsma-Rus ... Nucleic Acid Therapeutics is under the editorial leadership of Co-Editors-in-Chief Bruce A. Sullenger, PhD, Duke Translational ... Nucleic Acid Therapeutics is a rapid-publication Journal, with peer review averaging 25 days from submission to first decision ...
more infohttp://www.liebertpub.com/overview/nucleic-acid-therapeutics-formerly-oligonucleotides/601/

therapeutics News, Researchtherapeutics News, Research

Norovirus structures could help develop therapeutics to fight food-borne illness Noroviruses are a leading cause of food-borne ... Harnessing the power of skin microbiome to develop new therapeutics As scientific researchers continue to investigate the ... research team led by scientists at the University of Alabama at Birmingham has identified a potential target for therapeutics ... therapeutics) or support overall skin health (cosmetics). ...
more infohttps://www.news-medical.net/?tag=/therapeutics

RNAi therapeuticsRNAi therapeutics

Promising RNAi therapeutics research also is advancing in academic labs. In March of last year, John Rossi at the Beckman ... RNAi therapeutics start acting when a short piece of double-stranded RNA (somewhere between 20 and 25 or so nucleotides) enters ... "Merck recognized from the outset that developing RNAi therapeutics would be a long-term investment and not a quick path to ... That re-entry might be just around the corner, says Barry Greene of Alnylam Pharmaceuticals, an RNAi therapeutics company that ...
more infohttp://www.asbmb.org/asbmbtoday/asbmbtoday_article.aspx?id=12246&page_id=3

Chemotherapy | therapeutics | Britannica.comChemotherapy | therapeutics | Britannica.com

therapeutics: Chemotherapy. Chemotherapy is the treatment of disease using chemical agents that are intended to eliminate the ... therapeutics: Chemotherapy. Chemotherapy is the treatment of disease using chemical agents that are intended to eliminate the ...
more infohttps://www.britannica.com/science/chemotherapy

Lavage | therapeutics | Britannica.comLavage | therapeutics | Britannica.com

Other articles where Lavage is discussed: pulmonary alveolar proteinosis: …out of the lungs (lavage). One lung at a time is rinsed with a saltwater solution introduced through the windpipe. The fluids drawn back out of the lungs have been found to have a high content of fat. Sometimes the lesions totally clear up after one procedure, but subsequent…
more infohttps://www.britannica.com/science/lavage

OPEXA THERAPEUTICS, INC. 424B3OPEXA THERAPEUTICS, INC. 424B3

In June 2006, the Company (i) changed its name to Opexa Therapeutics, Inc. from PharmaFrontiers Corp. and (ii) effected a one- ... Exhibit 3.1 Articles of Amendment and Restatement of the Articles of Incorporation of Opexa Therapeutics, Inc. (1) ... Pursuant to 18 U.S.C. Section 1350, the undersigned Officer of Opexa Therapeutics, Inc. (the "Company"), hereby certifies, to ... Pursuant to 18 U.S.C. Section 1350, the undersigned Officer of Opexa Therapeutics, Inc. (the "Company"), hereby certifies, to ...
more infohttps://www.sec.gov/Archives/edgar/data/1069308/000115752306008508/a5210533.htm

Drugs and therapeutics | The BMJDrugs and therapeutics | The BMJ

We use cookies to improve our service and to tailor our content and advertising to you. More info Close You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our cookies policy Close ...
more infohttps://www.bmj.com/specialties/drugs-and-therapeutics

Biological Therapeutics | University of OxfordBiological Therapeutics | University of Oxford

A one-week module of the MSc in Experimental Therapeutics. Offered by the Department of Oncology and the Department for ... Biological Therapeutics. A one-week module of the MSc in Experimental Therapeutics. Offered by the Department of Oncology and ... The Biological Therapeutics course will provide students with the opportunity to learn more about and discuss the following ...
more infohttp://www.ox.ac.uk/research/innovation-and-partnership/news-and-events/2015-10-05-biological-therapeutics

Wiley-VCH - Advanced TherapeuticsWiley-VCH - Advanced Therapeutics

Advanced Therapeutics provides a unique multidisciplinary forum for the best research in the next generation of therapeutics, ... Medicinal chemistry, including discovery and design of (macro)molecular therapeutics *Personalized and precision medicine, ...
more infohttps://www.wiley-vch.de/de/shop/journals/1034-advanced-therapeutics-2313-de

Is Intellia Therapeutics a Buy?Is Intellia Therapeutics a Buy?

Intellia Therapeutics ended March with $297 million in cash, which ranked behind both Editas Medicine and CRISPR Therapeutics. ... CRISPR Therapeutics (NASDAQ: CRSP), valued at $2.7 billion, was the first to advance a drug to clinical trials, and it has ... Intellia Therapeutics is behind its peers when it comes to advancing assets into clinical trials, but it all comes down to the ... Intellia Therapeutics, on the other hand, is targeting liver diseases with an in vivo approach. The organ requires a very ...
more infohttps://finance.yahoo.com/news/intellia-therapeutics-buy-164123421.html

Acorda Therapeutics rises on Ampyra studyAcorda Therapeutics rises on Ampyra study

Shares of Acorda Therapeutics Inc. jumped Monday after the company said that its drug Ampyra helped stroke patients recover ... NEW YORK (AP) -- Shares of Acorda Therapeutics Inc. jumped Monday after the company said that its drug Ampyra helped stroke ...
more infohttps://www.yahoo.com/news/acorda-therapeutics-rises-ampyra-study-154616998.html?ref=gs

Pear Therapeutics | FierceBiotechPear Therapeutics | FierceBiotech

Pear Therapeutics aims to develop digital therapeutics that reproduce the changes seen in a patients neural circuitry ... But one of the main goals of Pear is to build a discovery engine for digital therapeutics. The companys development team scans ... The company aims to develop digital therapeutics that reproduce the changes seen in a patients neural circuitry following ... as well as to help continue to gather the clinical evidence needed to drive adoption of the digital therapeutics. ...
more infohttps://www.fiercebiotech.com/special-report/pear-therapeutics

PsiOxus Therapeutics | FierceBiotechPsiOxus Therapeutics | FierceBiotech

PsiOxus thinks it has figured out how to systemically deliver viruses that only replicate in tumor cells. That turned heads at Bristol-Myers Squibb, which struck two deals with PsiOxus last year and provided a launchpad for a pipeline that uses viruses to directly kill cancer cells.
more infohttps://www.fiercebiotech.com/special-report/psioxus-therapeutics